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Background: The 300IR (index of reactivity) 5-grass pollen tablet has favorable short-term and sustained clinical
efficacy in patients with grass pollen-induced allergic rhinoconjunctivitis (ARC). Here, we report maintenance of
efficacy and safety over 2 years following treatment discontinuation.
Methods: Randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 trial in patients aged
18–50 years with ARC. During study years 1–3, patients received a daily sublingual tablet containing either 300IR
5-grass pollen extract or placebo, according to a discontinuous pre- and coseasonal protocol. Study years 4 and 5
were treatment-free. In response to health authorities’ recommendations, the daily combined score (DCS) was
assessed in a post-hoc analysis as the efficacy endpoint. Components of the DCS were daily rhinoconjunctivitis total
symptom score (DRTSS) and daily rescue medication score (DRMS).
Results: 633 patients with ARC were randomized to placebo (n = 219) or 300IR 5-grass pollen tablet, beginning
4 months (4 M, n = 207) or 2 months (2 M, n = 207) prior to the estimated start of the grass pollen season and
continuing until season’s end. During the first post-treatment year, a statistically significant difference versus placebo
in least squares (LS) mean DCS was noted in patients previously receiving active treatment (300IR (2 M) point estimate:
−0.16, 95% confidence interval (CI95%): [−0.26, −0.06], p = 0.0019; −31.1%; 300IR (4 M) point estimate: −0.13, CI95%:
[−0.23, −0.03], p = 0.0103, −25.3%). During the second post-treatment year, patients in the 300IR (4 M) group, but not
the 300IR (2 M) group, showed a statistically significant difference in LS mean DCS versus placebo (point estimate:
−0.11, CI95%: [−0.21; 0.00], p = 0.0478, −28.1%). This significant efficacy seen during the post-treatment years in patients
previously treated with 5-grass pollen tablet compared favorably with that during the 3 prior years of active treatment.
A statistically significant difference versus placebo was also noted in secondary efficacy measures in both post-
treatment years (except for DRTSS in year 5). In the absence of any active treatment, the safety profile was similar in
the active groups versus placebo group during either post-treatment year.
Conclusions: In adults with grass pollen-associated ARC, 5-grass pollen tablet therapy beginning 4 months before the
pollen season and continuing to season’s end demonstrated efficacy across all variables during active treatment, and
this effect was prolonged for up to 2 years post-treatment.
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Allergic rhinitis (AR) affects an estimated 500 million
people globally, and is increasing in prevalence in many
countries [1]. AR places a heavy burden on healthcare
resources, and is associated with substantial indirect
costs related to absenteeism from work and decreased
productivity [2].
The 300IR (index of reactivity) 5-grass pollen tablet
(Oralair®; Stallergenes, Antony, France) is approved as
allergen immunotherapy (AIT) for the treatment of con-
firmed grass pollen-induced AR with or without con-
junctivitis in over 30 countries worldwide and is the first
registered AIT tablet in the United States. Its short-term
clinical efficacy has been well-established through a large
number of studies conducted in adults and children,
which demonstrated consistent results [3-5]. The 5-grass
pollen tablet is effective from the first pollen season in
controlling the symptoms of allergic rhinoconjunctivitis
(ARC) and reducing the need for symptomatic medica-
tion in all types of patients, irrespective of mono- or
polysensitization status, symptom severity and the pres-
ence or absence of co-morbid mild asthma [6,7].
In clinical trials, the efficacy of immunotherapy for
ARC was often evaluated using the average rhinocon-
junctivitis total symptom score (ARTSS) [8]. For ethical
reasons, patients are provided with rescue medications,
which may alleviate symptoms. Their use can result in a
corresponding reduction in symptom scores, which
may decrease the mean difference between the active-
treatment and placebo groups [8]. Based on this rationale,
World Allergy Organization (WAO) taskforce recommen-
dations on the methodological aspects of immunotherapy
clinical trials propose that a combined daily symptom and
rescue medication score be used as the primary outcome
measure [9]. Similarly, the European Academy of Allergy
and Clinical Immunology (EAACI) Immunotherapy Inter-
est Group also recommends the use of a homogenous
combined symptom and medication score as a standard-
ized method to balance both symptoms and the need for
antiallergic medication in an equally weighted manner
[10]. Such a standardized combined score can provide a
simple analysis of the daily burden of disease [10]. Com-
bining symptom and medication scores with equal im-
portance is also associated with a large effect size, which is
powered to demonstrate treatment efficacy [10].
The European Medicines Agency (EMA) guidance on
development of products for allergen immunotherapy
states that a long-term clinical study is necessary to
demonstrate maintenance of efficacy over 3 treatment
years, and a disease-modifying effect after treatment dis-
continuation, both of which are key goals of specific AIT
and distinguish it from other allergy treatments [11]. It
has previously been shown that the efficacy of the 300IR
5-grass pollen tablet is sustained when administereddiscontinuously as a pre- and coseasonal treatment (with
a treatment-free period for the other months of the year,
starting after the season ends), over 3 consecutive years
in adults with moderate to severe ARC (study VO53.06)
[12]. Furthermore, this favorable efficacy persists for at
least one season after treatment is discontinued [13].
Here, we report long-term efficacy and safety results
from study VO53.06 during the first (year 4) and second
(year 5) seasons following treatment discontinuation,
using the daily combined score (DCS).
Methods
Study design
The design and detailed results from the first 4 years
of this randomized, double-blind, placebo-controlled,
parallel-group, multicenter, Phase 3 trial conducted at
48 sites in Austria, Canada, Czech Republic, Denmark,
France, Germany, Italy, Poland, Russia and Slovakia,
have been reported previously [12,13]. The trial origin-
ally included 3 years of active treatment and 1 year of
treatment-free follow-up to investigate the long-term
efficacy of the 300IR 5-grass pollen tablet. At the end
of year 3, the Data Safety Monitoring Board recom-
mended that the study be extended for an additional
year of treatment-free follow-up (year 5).
In brief, during the first 3 years of the study (2007–
09), patients were randomized 1:1:1 using a computer-
generated list to either placebo or 300IR 5-grass pollen
tablet, administered according to a discontinuous pre-
and coseasonal protocol beginning at 4 or 2 months
(300IR (4 M) and 300IR (2 M), respectively) prior to the
expected start of the grass pollen season and maintained
until season’s end. Patients did not receive investiga-
tional product during years 4 and 5 of the study (2010–
11). Patients and investigators remained blinded until
the end of the fifth year of the study.
The study protocol (European Union Drug Regulating
Authorities Clinical Trials (EudraCT) number 2006-
003258-98) was reviewed and approved by local regula-
tory authorities and independent ethics committees in
each country, and the study and year 5 extension were
conducted according to the Declaration of Helsinki and
Good Clinical Practice-International Conference on Har-
monisation guidelines. Patients provided their written in-
formed consent before the start of any study-associated
procedure, and reconsented prior to participation in the
year 5 extension.
Patients
Patients were aged 18–50 years with documented grass
pollen-related ARC for at least the two previous grass
pollen seasons, a positive skin-prick test (wheal diameter
>3 mm) to 5-grass-pollen-mix extract, Phleum pratense
(timothy grass)-specific serum IgE ≥0.7 kU/L, and a
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(RRTSS) ≥12 (on a 0–18 scale), based on the most severe
days in the grass pollen season preceding enrolment.
Exclusion criteria were ARC symptoms during the
grass pollen season due to allergens other than grass
pollen, asthma requiring treatment with more than a
beta-2 agonist, or presence of any other disease that
might affect the participation or outcome of the study.
Treatment
During the first 3 years of the study, patients received a
daily sublingual tablet containing either 300IR 5-grass
pollen extract or placebo, according to the discontinuous
dosing schedule described above. Years 4 and 5 of the
study (i.e., the fourth and fifth pollen season) were 300IR
5-grass pollen tablet treatment-free.
To maintain blinding, active and placebo tablets were
identical in appearance and taste, and patients random-
ized to the 2 M dosing regimen received placebo for the
2 months prior to starting active treatment.
The use of oral antihistamines, antihistamine eye drops,
nasal corticosteroids and oral corticosteroids as rescue
medications was permitted throughout the study, follow-
ing a stepwise regimen defined in the study protocol, in
which oral corticosteroids could only be considered once
the other types of medications had proven inadequate at
managing severe or intolerable ARC symptoms.
Grass pollen season
During each pollen season, pollen counts were moni-
tored and recorded daily in the regions where study sites
were located. The pollen period for statistical analysis
was defined as starting on the first of 3 consecutive days
with a grass pollen count of ≥30 grains/m3 and ending
on the last of 3 consecutive days with a grass pollen
count of ≥30 grains/m3.
Outcome measures
The main outcome measures have been reported previ-
ously [12,13]. From approximately 3 weeks before each
pollen season until the end of that season, patients re-
corded in a daily diary six individual rhinoconjunctivitis
symptom scores (RSSs: sneezing, rhinorrhea, nasal prur-
itus, nasal congestion, ocular pruritus and watery eyes)
and use of rescue medication during the previous 24 h.
Severity of symptoms was rated using a 4-point descrip-
tor scale from 0 (absent) to 3 (severe), and the sum of all
six individual RSSs comprised the rhinoconjunctivitis
total symptom score (RTSS, range 0–18) [14]. The res-
cue medication score (RMS, range 0–3) was calculated
using the following scale: 0, no rescue medication; 1, use
of antihistamine (oral and/or eye drops); 2, use of nasal
corticosteroid; and 3, use of oral corticosteroid. If a pa-
tient took two or more rescue medications on the sameday, the highest score was used for the RMS [14]. Effi-
cacy analyses were performed on the full analysis set
(FAS). In contrast to other symptoms scores, no last
observation carried forward data adjustment is carried
out with the Average adjusted symptom score (AAdSS),
thereby reducing the potential for skewing of the data.
After the study had commenced, guidance from
health authorities and professional societies regarding
the primary efficacy endpoint of AIT clinical trials sub-
sequently recommended the use of a score that con-
siders both symptoms and rescue medication use, to
avoid an underestimation of symptoms severity. In re-
sponse to this guidance, the average adjusted symptom
score (AAdSS) [14] was introduced as primary efficacy
measure [12,13]. Results for the AAdSS have been re-
ported previously [12,13].
The AAdSS was calculated per patient as the average
of the non-missing daily adjusted symptom scores
(AdSSs, range 0–18), which were derived from the daily
RTSS (DRTSS) adjusted for rescue medication use over
2 consecutive days [14].
Secondary efficacy measures included individual RSSs;
Average Combined Score (ACS, range 0–3); DRTSS;
daily RMS (DRMS); ARTSS (range 0–18); and average
RMS (range 0–3). All average scores were patient-
specific and calculated as the average of the non-missing
daily scores during the pollen season while the patient
was on treatment [14]. In response to regulatory author-
ities recommending use of a combined symptom and
rescue medication score [9], a post-hoc analysis was per-
formed using an alternative measure for the evaluation
of efficacy: DCS (range 0–3), which assigns equivalent
weighting to both symptom and rescue medication
scores, and is calculated as [(DRTSS/6) + DRMS)]/2
[8,14]. DCS is a genuine combined score, unlike AdSS,
which is not a combined score per se, but a symptom
score that is adjusted by taking into account the use of
allergy rescue medication [15].
In this paper, results using the alternative efficacy
measure, DCS, are presented.
Safety
Safety was assessed through monitoring of adverse
events (AEs), laboratory parameters, physical examin-
ation and vital signs. AEs were recorded throughout the
study and classified according to the Medical Dictionary
for Regulatory Activities (MedDRA; version 9.1).
Sample size
The results of a previous pivotal, dose-finding study in
Europe of the 5-grass pollen tablet for the treatment of
ARC [4] suggested that a sample size of 144 patients per
group would have 80% power to detect a difference of
20% between the active-treatment and placebo groups in
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mary endpoint), given a type I error of 5% and a com-
mon standard deviation (SD) of 3.6.
For post-treatment, long-term efficacy assessment,
assuming a screening failure rate of 12% each treatment
year and a comparable 12% drop-out rate for the fourth
year, 127 patients per group would have 75% power to
detect a 20% difference in AAdSS for post-treatment
long-term efficacy. No formal pre-defined power calcula-
tion was performed for the analysis of year 4 and year 5.
Statistical analyses were performed using SAS® soft-
ware (version 9.1.3, SAS Institute Inc., Cary, NC, USA).
The safety sets in year 4 and year 5 included all patients
who received ≥1 dose of 300IR 5-grass pollen tablet dur-
ing years 1–3, and who completed the first visit in year 4
(visit 19) or year 5 (visit 23), respectively. The FAS for
years 1–3 included all patients who started treatment
and had ≥1 AdSS recorded during the pollen season of
that year. The FAS for years 4 and 5 included all patients
who started the respective post-treatment year and had
≥1 AdSS recorded during the pollen season of that year.
The per-protocol sets included all FAS patients with ≥14
valid AdSS days during the pollen season or valid AdSS
days for ≥50% of the pollen period, and who completed
the study without any major protocol deviations.
Average scores were analyzed using a linear model and
an analysis of covariance (ANCOVA) with pooled site,
age, gender, asthma status and sensitization status as co-
variates. The post-hoc analysis of the DCS was performed
using a linear mixed model with repeated measures and
an ANCOVA. Variables which could potentially impact
the clinical score (pooled site, age, gender, asthma status
and sensitization status) were included in the model as co-
variates. Treatment was the main effect and the day was
the indicator of time. All effects were fixed, except the
patient who was considered as a random effect. A point
estimate and 95% confidence interval (CI95%) for the dif-
ference in adjusted means between active-treatment and
placebo groups were calculated. The threshold for statis-
tical significance was set at p ≤ 0.05 and all inferential tests
were two-sided.
DRTSS and DRMS, the components of the DCS, were
analyzed similarly to the DCS.
Results
Study population
Demographics and baseline characteristics for the
FASYear 4 have already been published [13]. Data from
FASYear 5 were well-balanced and comparable across
treatment groups (Table 1). Randomized patients in
the FASYear 5 had moderate-to-severe grass pollen-
associated ARC, as denoted by a mean RRTSS of 14.1
(SD: 1.7), for a mean duration of 12.8 years (SD: 9.0).
The majority (59.4%) of patients were polysensitizedto grass pollen and another allergen, and Global Initiative
for Asthma (GINA) treatment Step I for asthma [16] was
reported in 12.7% of patients.
Overall, 633 patients with ARC were randomized to
receive placebo (n = 219) or 300IR 5-grass pollen tablet
starting 4 months (4 M; n = 207) or 2 months (2 M; n =
207) before the estimated start of the grass pollen season
(Figure 1). Of the 457 patients who completed year 3, 15
patients withdrew from the study before the start of year
4 [placebo: consent withdrawn (n = 5), protocol non-
compliance (n = 1), other reason (n = 1); 300IR (2 M):
consent withdrawn (n = 3), pregnancy (n = 1), protocol
non-compliance (n = 1); 300IR (4 M): consent withdrawn
(n = 1), ineligibility (n = 2)]. The year 4 safety set in-
cluded 442 patients (placebo, n = 156; 300IR (2 M),
n = 141; 300IR (4 M), n = 145), with the FASYear 4 com-
prising 435 patients (placebo, n = 155; 300IR (2 M),
n = 137; 300IR (4 M), n = 143).
Of the 433 patients who completed year 4 (post-
treatment year 1), 51 withdrew from the study before
the start of year 5, with the majority citing a wish not
to participate [placebo: consent withdrawn (n = 12), lack
of efficacy requiring another treatment to be prescribed
(n = 1), other reason (n = 7); 300IR (2 M): consent with-
drawn (n = 9), lost to follow-up (n = 1), other reason (n = 6);
300IR (4 M): consent withdrawn (n = 10), planning to
conceive (n = 1), other reason (n = 4)]. At the end of year
5, the safety set included 382 patients (placebo, n = 134;
300IR (2 M), n = 120; 300IR (4 M), n = 128), with the
FASYear 5 comprising 377 patients (placebo, n = 133;
300IR (2 M), n = 117; 300IR (4 M), n = 127). This repre-
sents a loss of 9.1% (n = 58) of patients from the end of
year 4 of the study, and 40.4% (n = 256) of patients,
compared with the initial year 1 population.
Notably, those patients who withdrew from the study
between year 4 and the end of year 5 had markedly more
severe ARC symptoms than those who continued, as
measured by ARTSS. Mean ARTSS scores (± SD) for the
patients who discontinued after year 4 were 5.68 ± 3.37
(placebo, n = 22), 3.15 ± 3.11 (300IR (2 M), n = 20) and
5.01 ± 4.74 (300IR (4 M), n = 16), compared with 4.04 ±
3.21 (placebo, n = 133), 3.22 ± 3.12 (300IR (2 M), n = 117)
and 3.30 ± 3.19 (300IR (4 M), n = 127) for those patients
who continued into year 5. Moreover, irrespective of
study year, among patients who discontinued, those in
the placebo group experienced more severe ARC symp-
toms than their counterparts in the 300IR (4 M) group.
Similar differences in ARC symptom severity between
patients receiving placebo or active treatment were
found using ACS. Patients in the placebo group who
discontinued before year 5 had a higher ACS (0.79) than
those in the active-treatment groups who withdrew
from the study at this time (0.49 and 0.70 for 300IR
(2 M) and 300IR (4 M), respectively).
Table 1 Demographics and baseline characteristics of the study population (FASYear 5, N = 377)
Parameter Treatment group
Placebo n = 133 300IR (2 M) n = 117 300IR (4 M) n = 127 Total N = 377
Gender, n (%)
Male 79 (59.4) 71 (60.7) 81 (63.8) 231 (61.3)
Female 54 (40.6) 46 (39.3) 46 (36.2) 146 (38.7)
Age, years
n 133 117 127 377
Mean (SD) 30.1 (8.7) 30.9 (7.8) 30.5 (8.5) 30.5 (8.3)
Range 18–49 18–51 18–49 18–51
Body mass index, kg/m2
n 132 117 127 376
Mean (SD) 23.9 (4.3) 24.3 (3.9) 24.2 (3.7) 24.1 (4.0)
Range 15.6–42.4 17.3–35.1 17.2–35.1 15.6–42.4
Duration of ARC, years
n 133 117 127 377
Mean (SD) 12.5 (9.0) 12.9 (8.8) 13.0 (9.2) 12.8 (9.0)
Range 1.6–44.0 1.5–39.0 1.5–42.1 1.5–44.0
RRTSS
n 133 117 127 377
Mean (SD) 14.0 (1.7) 13.9 (1.8) 14.2 (1.7) 14.1 (1.7)
Range 12–18 12–18 12–18 12–18
Asthma status, n (%)
Yes 19 (14.3) 13 (11.1) 16 (12.6) 48 (12.7)
No 114 (85.7) 104 (88.9) 111 (87.4) 329 (87.3)
Sensitization status, n (%)
Monosensitized 53 (39.8) 47 (40.2) 53 (41.7) 153 (40.6)
Polysensitized 80 (60.2) 70 (59.8) 74 (58.3) 224 (59.4)
2 M, 2-month preseasonal dosing protocol; 4 M, 4-month preseasonal dosing protocol; ARC, allergic rhinoconjunctivitis; FAS, full analysis set; IR, index of reactivity;
RRTSS, retrospective rhinoconjunctivitis total symptom score; SD, standard deviation.
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A statistically significant difference versus placebo in
least squares (LS) mean DCS was noted in patients in the
active-treatment groups during the first post-treatment
year (FASYear 4) (300IR (2 M) point estimate: −0.16,
CI95%: [−0.26, −0.06], p = 0.0019, −31.1%; 300IR (4 M)
point estimate: −0.13, CI95%: [−0.23, −0.03], p = 0.0103,
−25.3%) (Figure 2A). During the second post-treatment
year (FASYear 5), patients in the 300IR (4 M) group, but
not the 300IR (2 M) group, showed a statistically signifi-
cant difference in LS mean DCS, compared with placebo
(point estimate: −0.11, CI95%: [−0.21; 0.00], p = 0.0478),
which corresponds to a relative LS mean difference of
−28.1%. This compares favorably with the significant effi-
cacy of the 5-grass pollen tablet after 3 pollen seasons of
discontinuous pre- and coseasonal treatment (FASYear 3),
during which both the 300IR (4 M) and 300IR (2 M)
groups showed a statistically significant difference in
DCS, compared with placebo (p < 0.0001) (Figure 2A).As was observed for DCS, a similar statistically signifi-
cant difference versus placebo was noted in all other effi-
cacy variables after years 4 and 5, with the exception of
DRTSS (both 300IR (2 M) and (4 M) groups) (Figure 2B),
AAdSS (300IR (4 M)) and ARTSS in year 5 (300IR
(2 M)). Scores after treatment cessation still favored the
active-treatment groups, as during the active-treatment
period. The DRMS remained stable with the transition
from active treatment into the treatment-free years 4
and 5 (Figure 2C).
Of note, DCS, DRTSS and DRMS were similar from
years 2 to 5 in the active-treatment groups, whereas they
decreased consistently in the placebo group (Figure 2).
This trend for active-treatment values and steadily de-
creasing placebo values over the course of the study was
also observed for LS mean DRTSS (300IR (2 M): 3.66,
2.42, 2.07, 2.44, 1.73 and 300IR (4 M): 3.84, 2.61, 2.18,
2.70, 1.92 versus placebo: 4.31, 3.81, 3.55, 3.52, 2.51 for
FASYear 1–5, respectively) and LS mean DRMS (300IR
Figure 1 Flow-chart of patients per treatment group and treatment season throughout the three pre- and coseasonal treatment
periods (years 1–3) and post-treatment period (years 4 and 5). 2 M, 2-month preseasonal dosing protocol; 4 M, 4-month preseasonal dosing
protocol; FAS, full analysis set; IR, index of reactivity.
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0.26, 0.25, 0.31, 0.23 versus placebo: 0.63, 0.49, 0.41,
0.42, 0.34 for FASYear 1–5, respectively). For the com-
parison of DRTSS at year 4 (FASYear 4) and year 5
(FASYear 5), this trend was particularly pronounced,
with the difference in LS mean scores being −0.71 and
−0.78 for the 300IR (2 M) and 300IR (4 M) groups,
respectively, versus −1.01 for placebo.
It is important to note that the difference versus placebo
for the secondary criterion, ACS, was statistically signifi-
cant at year 5 (FASYear 5) for the 300IR (4 M) group (point
estimate: −0.11, CI95%: [−0.21, −0.00], p = 0.0473, −20.7%),
but not for the 300 IR (2 M) group (point estimate: −0.11,
CI95%: [−0.22, 0.00], p = 0.0525, −20.7%).
Safety
Safety profiles in the treatment-free years 4 and 5 were
consistent between all groups of patients who previously
received placebo or active treatment, with no unexpected
signal identified during either post-treatment year. There
were no reports of autoimmune disorders judged to be re-
lated to study treatment, and no notable differences re-
garding laboratory results, vital signs or physical
examinations between treatment groups during the post-treatment period. One post-treatment AE of oral allergy
syndrome occurring in year 4 in a patient previously
assigned to therapy with the 300IR (4 M) regimen was
judged to be related to the 300IR 5-grass pollen tablet.
Discussion
In the first and second post-treatment years of this ran-
domized, double-blind, placebo-controlled, multicenter
trial, a statistically significant and clinically relevant dif-
ference was observed between the 300IR (4 M) group
and placebo for the DCS, DRTSS and DRMS (relative
LS mean differences: first post-treatment year: −25.3%,
−23.4% and −27.9% respectively; second post-treatment
year: −28.1%, −23.5% and −33.8%, respectively). These
findings confirm that the favorable long-term ARC
symptom management of the 300IR 5-grass pollen tablet
extends to 2 years post-treatment, building on the re-
sults of previous analyses of this study [12,13]. When
considering absolute values across the study, the scores
for patients in the active-treatment groups remained
relatively static between years 3 to 5, in contrast to
scores from patients in the placebo group, which steadily
decreased due to premature withdrawal of patients with
severe ARC symptoms.
Figure 2 Repeated measures analysis of covariance of the DCS (A), DRTSS (B) and DRMS (C) per year of the study (FASYear 1–5).
ap < 0.0001,
bp < 0.0005, cp < 0.001, dp < 0.005, ep < 0.01, fp < 0.05 for comparison vs placebo. DCS, daily combined score; DRMS, daily rescue medication score;
DRTSS, daily rhinoconjunctivitis total symptom score; FAS, full analysis set; IR, index of reactivity; LS, least squares; SE, standard error.
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patients, particularly those randomized to placebo, is an
inherent drawback of long-term studies. The present
study was initially conducted to assess post-treatment
efficacy over three treatment periods and a fourth subse-
quent immunotherapy-free year. The study was later ex-
tended to include a fifth immunotherapy-free year. This
extension was accompanied by the withdrawal of 51
patients prior to the start of the final year. It is assumed
that patients with the most severe ARC symptoms in theplacebo group would have a higher chance of discon-
tinuing before the end of the study, and this loss of
patients from the placebo group can artificially reduce
the difference in estimated treatment effect and intro-
duce bias into the data. Nevertheless, significant post-
treatment efficacy was noted in patients in the 300IR
(4 M) group, as judged by DCS, which is the approved
treatment scheme. In the second post-treatment year,
the difference versus placebo in DCS for the 300IR
(2 M) group was not statistically significant, but reached
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a trend towards improved efficacy was observed in the
300IR (2 M) group, the lack of statistical significance ver-
sus placebo may be due to the lower number of patients
in this group, compared with the 300IR (4 M) group.
However, no firm conclusion can be drawn.
A consistent yearly decrease in patients with the most
severe ARC symptoms, receiving placebo, was also
observed in a comparable 5-year study in patients with
grass pollen-induced ARC, which investigated the long-
term efficacy of continuous treatment with a 1-grass
pollen tablet preparation [17]. Significant efficacy was
confirmed in this study during both the on-treatment
and subsequent post-treatment years, using a daily com-
bined symptom medication score that was weighted
towards the use of rescue medication. However, in con-
trast to the present study, in which the use of rescue
medication remained fairly constant throughout all study
years, there was a marked increase in daily rescue medi-
cation use in the 1-grass pollen tablet study during the
post-treatment period, compared with the preceding
years on active treatment [17,18].
In the original design of the present study, the AAdSS
was pre-specified as the primary efficacy measure. Of
note, in year 5, AAdSS scores did not reach statistical
difference for the 300IR (4 M) group, while they did for
the 300IR (2 M) group, compared with placebo. The
AAdSS is a symptom score that is adjusted according to
allergy rescue medication use [15], which was developed
by Stallergenes. However, while accepted by European
health authorities, it is not a true combined scoring in-
strument like the DCS [15]. Weaknesses of the AAdSS
are that it does not account for the magnitude of the
effect of different classes of rescue medication, and the
duration of adjustment is set to 2 days as a conservative
approach, leading to an overestimation of rescue medi-
cation use.
Health authorities, and the WAO and EAACI, have
proposed that a combined symptom and rescue medi-
cation score, in particular one assigning equivalent
importance of the two components, is utilized in
ARC trials [9,10]. Combined scores are comprehen-
sive efficacy endpoints that also offer a number of
benefits, including simplicity and ease of application
[14]. Daily scores are either recorded by patients on a
daily basis or are derived daily, whereby each day is a
separate time point [10]. The lack of a standardized
scoring method for assessing DCS is a recognized
issue in AIT research and several different approaches
have been used in the field, in addition to the one
employed in this study [15]. Of note, differences ver-
sus placebo in the ACS, planned in the protocol as a
secondary criterion, were also statistically significant
for both active treatment groups, with the exceptionof 300IR (2 M) in the second post-treatment year
(mirroring the results for DCS).
Although few studies have investigated the optimal
duration of AIT, current recommendations advise treat-
ing patients for 3–5 years [11,19-21]. In line with these
recommendations, the study reported here investigated
long-term, post-treatment efficacy of the 300IR 5-grass
pollen tablet when given pre- and coseasonally for 3
consecutive years, and monitored efficacy for the follow-
ing 2 years. It may also be valuable to investigate extend-
ing the duration of treatment beyond 3 years, or to
individualize the duration of immunotherapy.
As would be expected in an untreated patient popula-
tion, there were no safety signals during post-treatment
years.
The 300IR 5-grass pollen tablet offers a number of
benefits. This unique pre- and coseasonal immunother-
apy is the first oral treatment with a consistent, well-
balanced allergen extract that mimics natural exposure
and sensitization [22], and over 5 years of clinical and
real-world experience has demonstrated its efficacy and
safety as a therapy for grass pollen allergy [23]. Results
of the present analysis add to the existing body of evi-
dence, demonstrating that the efficacy in terms of ARC
symptom control over 3 years of treatment is present for
2 years after stopping treatment.
Conclusions
This is the first long-term study of discontinuous treat-
ment with the 300IR 5-grass pollen tablet that indicates
efficacy for up to 2 years post-treatment. Consistent
post-hoc analysis results with the 300IR 5-grass pollen
tablet beginning 4 months before the pollen season and
continuing to season’s end were achieved across all effi-
cacy variables, and stabilization of ARC symptoms was
attained during both active treatment, and in the 2 sub-
sequent years without treatment.
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